Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.
GT Apeiron is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents.Learn more
Please follow our News page to learn about recent updates
Apr 16, 2021Read more
Our team and partners bring together deep expertise in applied AI and drug discovery to enable efficient and scalable discovery and development of novel drugs.